✦ LIBER ✦

Tolvaptan, an Orally Active Vasopressin V2-Receptor Antagonist-Pharmacology and Clinical Trials

✍ Scribed by Miyazaki, Toshiki ;Fujiki, Hiroyuki ;Yamamura, Yoshitaka ;Nakamura, Shigeki ;Mori, Toyoki

Book ID: 109106182
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 252 KB
Volume: 25
Category: Article
ISSN: 0897-5957
DOI: 10.1111/j.1527-3466.2007.00001.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EFFECTS OF AN ORALLY ACTIVE VASOPRESSIN

EFFECTS OF AN ORALLY ACTIVE VASOPRESSIN V1 RECEPTOR ANTAGONIST

✍ L. M. Burrell; P. A. Phillips; J. Stephenson; J. Risvanis; A-M. Hutchins; C. I. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB

Tolvaptan, a selective oral vasopressin

Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats

✍ Tadashi Okada; Toshifumi Sakaguchi; Ikuji Hatamura; Fumie Saji; Shigeo Negi; Har 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 695 KB

ChemInform Abstract: Synthesis and Chara

ChemInform Abstract: Synthesis and Characterization of Orally Active Nonpeptide Vasopressin V2 Receptor Antagonists.

✍ Takehiko Ohkawa; Tatsuya Zenkoh; Masayuki Tomita; Naomi Hosogai; Keiji Hemmi; Hi 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 31 KB 👁 2 views

ChemInform Abstract: Synthesis and Pharm

ChemInform Abstract: Synthesis and Pharmacological Activity of Metabolites of Vasopressin V1 Receptor Antagonist, OPC-21268.

✍ K. OTSUBO; J. MATSUBARA; T. OHTANI; Y. KAWANO; K. KITANO; S. MORITA; K. KONDO; Y 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 29 KB 👁 2 views

Pharmacological characterization of YM08

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist

✍ A. Tahara; M. Saito; T. Sugimoto; Y. Tomura; K. Wada; T. Kusayama; J. Tsukada; N 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 83 KB

Effects of satavaptan, a selective vasop

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

✍ Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management. Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been asses